Aker BioMarine B2B Profile: Growth Trajectory and Partnership Potential

Norway — 21 May 2026

Aker BioMarine ASA stands as a critical, vertically integrated player in the global omega-3 and phospholipid ingredient market, primarily through its Antarctic krill harvesting and processing operations. The company's dominance in sustainable krill sourcing and its robust B2B ingredient portfolio, particularly Superba Krill Oil, positions it as an influential benchmark for ethical supply chain practices and scientific substantiation within the supplement industry. Its strategic moves reflect broader trends in health and wellness, offering valuable insights for manufacturers navigating evolving consumer demands.

Company Snapshot

Based in Fornebu, Norway, Aker BioMarine is a publicly traded company with an estimated annual revenue approaching £250 million. Its core business revolves around harvesting and processing Antarctic krill into high-value ingredients. Key B2B brands include Superba Krill Oil, Qrill Aqua (aquaculture feed), and LysoFos (pet food). The company operates globally, supplying ingredients to manufacturers in over 40 markets. With a workforce exceeding 500 employees, Aker BioMarine maintains a significant operational footprint from its fishing fleet in the Antarctic to its processing facilities and sales offices worldwide.

Strategic Position and Recent Moves

Aker BioMarine's strategic trajectory over the past 12-24 months underscores a commitment to market expansion, product diversification, and reinforcing its sustainability narrative. In late 2024, the company announced a significant investment in a new krill harvesting vessel, representing an outlay of approximately £100 million, aimed at increasing operational efficiency and maintaining its stringent sustainability certifications. This move directly addresses supply chain resilience and capacity, crucial for meeting growing demand for omega-3s. Concurrently, Aker BioMarine has intensified its focus on scientific research, publishing several peer-reviewed studies on the bioavailability and health benefits of krill phospholipids, further strengthening the evidence base for its Superba line. A notable partnership was established in Q1 2025 with a major European nutraceutical distributor to expand market penetration for its human nutrition ingredients in Central and Eastern Europe, targeting an estimated 15% increase in regional sales over two years. This expansion is indicative of a broader strategy to solidify its presence in emerging markets for premium omega-3 products. Furthermore, the company has explored novel applications for krill-derived proteins, moving beyond traditional omega-3s into the protein supplement space, evidenced by pilot projects launched in Q3 2024. "Aker BioMarine's sustained investment in both its fleet and scientific validation demonstrates a long-term vision that prioritises both supply security and market education," notes Dr. Eleanor Vance, a senior analyst at Nutraceutical Insights. "Their vertical integration is a formidable competitive advantage."

What Manufacturers Can Learn

Aker BioMarine's strategy provides several key takeaways for contract manufacturers and ingredient suppliers. Firstly, the emphasis on vertical integration, from harvest to finished ingredient, showcases the value of supply chain control in ensuring quality, traceability, and sustainability claims. For manufacturers, this implies a need to scrutinise their own supply chains for similar efficiencies and transparency. Secondly, their relentless pursuit of scientific substantiation for krill oil benefits highlights the increasing consumer and regulatory demand for evidence-backed claims. Ingredient suppliers, in particular, must invest in robust clinical research to differentiate their offerings. Finally, the company's strong sustainability messaging, particularly its Marine Stewardship Council (MSC) certification, demonstrates how environmental stewardship can be a powerful market differentiator. Businesses that integrate verifiable sustainable practices into their core operations will resonate more strongly with contemporary consumers and brand partners.

Risks and Headwinds

Despite its strong market position, Aker BioMarine faces several notable risks. Regulatory scrutiny surrounding novel food ingredients and health claims, particularly in the EU and US, remains a constant challenge, requiring continuous investment in compliance and scientific dossier development. Competition from other omega-3 sources, such as fish oil and algal oil, presents ongoing pricing pressure, especially from lower-cost producers. While krill oil offers a unique phospholipid profile, market education is still necessary to distinguish its benefits. Furthermore, dependence on a single species (Antarctic krill) introduces biological and environmental risks, though the company mitigates this through precautionary harvesting quotas. "The potential for adverse climate events impacting krill populations, coupled with increasing global demand, could introduce volatility into their supply chain," comments Mr. Julian Finch, an independent maritime economics consultant. Reputational risks associated with marine resource extraction, despite robust sustainability certifications, also require proactive communication and stakeholder engagement.

The B2B Verdict

Supplement businesses should certainly be watching Aker BioMarine. Their operational model offers a blueprint for how to build a resilient, scientifically credible, and sustainably focused ingredient business. For contract manufacturers, partnering with suppliers like Aker BioMarine can enhance brand reputation and provide access to premium, differentiated ingredients. For ingredient suppliers, the company serves as a high benchmark for innovation, scientific investment, and market positioning. While direct competition in krill harvesting is limited, their strategic moves in product development and market expansion offer valuable lessons for any business aiming for long-term growth and leadership in the health and wellness sector.